- Home
- OCCI vs TLSI Comparison
OCCI vs TLSI Comparison
Compare OCCI & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCCI
- TLSI
- Stock Information
- Founded
- OCCI N/A
- TLSI 2010
- Country
- OCCI United States
- TLSI United States
- Employees
- OCCI N/A
- TLSI N/A
- Industry
- OCCI Trusts Except Educational Religious and Charitable
- TLSI Medical Specialities
- Sector
- OCCI Finance
- TLSI Health Care
- Exchange
- OCCI Nasdaq
- TLSI Nasdaq
- Market Cap
- OCCI 146.8M
- TLSI 160.4M
- IPO Year
- OCCI N/A
- TLSI N/A
- Fundamental
- Price
- OCCI $6.18
- TLSI $5.35
- Analyst Decision
- OCCI
- TLSI Strong Buy
- Analyst Count
- OCCI 0
- TLSI 5
- Target Price
- OCCI N/A
- TLSI $10.90
- AVG Volume (30 Days)
- OCCI 115.8K
- TLSI 43.7K
- Earning Date
- OCCI 12-11-2023
- TLSI 05-15-2025
- Dividend Yield
- OCCI 24.32%
- TLSI N/A
- EPS Growth
- OCCI N/A
- TLSI N/A
- EPS
- OCCI N/A
- TLSI N/A
- Revenue
- OCCI N/A
- TLSI $32,141,000.00
- Revenue This Year
- OCCI N/A
- TLSI $55.13
- Revenue Next Year
- OCCI $10.19
- TLSI $50.71
- P/E Ratio
- OCCI N/A
- TLSI N/A
- Revenue Growth
- OCCI N/A
- TLSI 46.20
- 52 Week Low
- OCCI $5.47
- TLSI $3.50
- 52 Week High
- OCCI $10.15
- TLSI $7.75
- Technical
- Relative Strength Index (RSI)
- OCCI 42.48
- TLSI 54.12
- Support Level
- OCCI $5.95
- TLSI $5.35
- Resistance Level
- OCCI $6.82
- TLSI $5.68
- Average True Range (ATR)
- OCCI 0.14
- TLSI 0.35
- MACD
- OCCI -0.06
- TLSI 0.05
- Stochastic Oscillator
- OCCI 28.09
- TLSI 71.79
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.